skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 54  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 next page
Show only
Refined by: Database: Open Access: PubMed Central remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Editorial: Response assessment of radioligand therapies
Editorial: Response assessment of radioligand therapies
Material Type:
Article 		Add to My Research

Editorial: Response assessment of radioligand therapies

Frontiers in oncology, 2022-07, Vol.12, p.904337-904337 [Peer Reviewed Journal]

Copyright © 2022 Lopci and Prasad 2022 Lopci and Prasad ;ISSN: 2234-943X ;EISSN: 2234-943X ;DOI: 10.3389/fonc.2022.904337 ;PMID: 35965585

Full text available

Citations Cited by
2
Nephrotoxicity after radionuclide therapies
Nephrotoxicity after radionuclide therapies
Material Type:
Article 		Add to My Research

Nephrotoxicity after radionuclide therapies

Translational oncology, 2022-01, Vol.15 (1), p.101295-101295, Article 101295 [Peer Reviewed Journal]

2021 ;Copyright © 2021. Published by Elsevier Inc. ;2021 Published by Elsevier Inc. 2021 ;ISSN: 1936-5233 ;EISSN: 1936-5233 ;DOI: 10.1016/j.tranon.2021.101295 ;PMID: 34847420

Full text available

Citations Cited by
3
Octreotide Does Not Inhibit Proliferation in Five Neuroendocrine Tumor Cell Lines
Octreotide Does Not Inhibit Proliferation in Five Neuroendocrine Tumor Cell Lines
Material Type:
Article 		Add to My Research

Octreotide Does Not Inhibit Proliferation in Five Neuroendocrine Tumor Cell Lines

Frontiers in endocrinology (Lausanne), 2018-04, Vol.9, p.146-146 [Peer Reviewed Journal]

COPYRIGHT 2018 Frontiers Research Foundation ;Copyright © 2018 Exner, Prasad, Wiedenmann and Grötzinger. 2018 Exner, Prasad, Wiedenmann and Grötzinger ;ISSN: 1664-2392 ;EISSN: 1664-2392 ;DOI: 10.3389/fendo.2018.00146 ;PMID: 29681888

Full text available

Citations Cited by
4
mTOR Inhibitors as Radiosensitizers in Neuroendocrine Neoplasms
mTOR Inhibitors as Radiosensitizers in Neuroendocrine Neoplasms
Material Type:
Article 		Add to My Research

mTOR Inhibitors as Radiosensitizers in Neuroendocrine Neoplasms

Frontiers in oncology, 2021-02, Vol.10, p.578380-578380 [Peer Reviewed Journal]

Copyright © 2021 Exner, Arrey, Prasad and Grötzinger. ;COPYRIGHT 2021 Frontiers Research Foundation ;Copyright © 2021 Exner, Arrey, Prasad and Grötzinger 2021 Exner, Arrey, Prasad and Grötzinger ;ISSN: 2234-943X ;EISSN: 2234-943X ;DOI: 10.3389/fonc.2020.578380 ;PMID: 33628728

Full text available

Citations Cited by
5
68Ga-PSMA-PET/CT for the evaluation of liver metastases in patients with prostate cancer
68Ga-PSMA-PET/CT for the evaluation of liver metastases in patients with prostate cancer
Material Type:
Article 		Add to My Research

68Ga-PSMA-PET/CT for the evaluation of liver metastases in patients with prostate cancer

Cancer imaging, 2019-06, Vol.19 (1), p.37-37, Article 37 [Peer Reviewed Journal]

COPYRIGHT 2019 BioMed Central Ltd. ;COPYRIGHT 2019 BioMed Central Ltd. ;2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s). 2019 ;ISSN: 1470-7330 ;ISSN: 1740-5025 ;EISSN: 1470-7330 ;DOI: 10.1186/s40644-019-0220-x ;PMID: 31186052

Full text available

Citations Cited by
6
Predictive and prognostic potential of pretreatment 68Ga-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA
Predictive and prognostic potential of pretreatment 68Ga-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA
Material Type:
Article 		Add to My Research

Predictive and prognostic potential of pretreatment 68Ga-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA

Frontiers in oncology, 2022-12, Vol.12, p.1066926-1066926 [Peer Reviewed Journal]

Copyright © 2022 Assadi, Manafi-Farid, Jafari, Keshavarz, Divband, Moradi, Adinehpour, Samimi, Dadgar, Jokar, Mayer and Prasad 2022 Assadi, Manafi-Farid, Jafari, Keshavarz, Divband, Moradi, Adinehpour, Samimi, Dadgar, Jokar, Mayer and Prasad ;ISSN: 2234-943X ;EISSN: 2234-943X ;DOI: 10.3389/fonc.2022.1066926

Full text available

Citations Cited by
7
Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor
Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor
Material Type:
Article 		Add to My Research

Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor

World journal of gastroenterology : WJG, 2009-12, Vol.15 (46), p.5867-5870

Copyright © Wanfang Data Co. Ltd. All Rights Reserved. ;2009 The WJG Press and Baishideng. All rights reserved. 2009 ;ISSN: 1007-9327 ;EISSN: 2219-2840 ;DOI: 10.3748/wjg.15.5867 ;PMID: 19998512

Full text available

Citations Cited by
8
A Physiologically Based Pharmacokinetic Model for In Vivo Alpha Particle Generators Targeting Neuroendocrine Tumors in Mice
A Physiologically Based Pharmacokinetic Model for In Vivo Alpha Particle Generators Targeting Neuroendocrine Tumors in Mice
Material Type:
Article 		Add to My Research

A Physiologically Based Pharmacokinetic Model for In Vivo Alpha Particle Generators Targeting Neuroendocrine Tumors in Mice

Pharmaceutics, 2021-12, Vol.13 (12), p.2132 [Peer Reviewed Journal]

2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 by the authors. 2021 ;ISSN: 1999-4923 ;EISSN: 1999-4923 ;DOI: 10.3390/pharmaceutics13122132 ;PMID: 34959413

Full text available

Citations Cited by
9
Optimization of Radiolabeling of a [ 90 Y]Y-Anti-CD66-Antibody for Radioimmunotherapy before Allogeneic Hematopoietic Cell Transplantation
Optimization of Radiolabeling of a [ 90 Y]Y-Anti-CD66-Antibody for Radioimmunotherapy before Allogeneic Hematopoietic Cell Transplantation
Material Type:
Article 		Add to My Research

Optimization of Radiolabeling of a [ 90 Y]Y-Anti-CD66-Antibody for Radioimmunotherapy before Allogeneic Hematopoietic Cell Transplantation

Cancers, 2023-07, Vol.15 (14), p.3660 [Peer Reviewed Journal]

2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2023 by the authors. 2023 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers15143660 ;PMID: 37509321

Full text available

Citations Cited by
10
Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer
Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer
Material Type:
Article 		Add to My Research

Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer

Cancers, 2021-07, Vol.13 (14), p.3607 [Peer Reviewed Journal]

2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 by the authors. 2021 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers13143607 ;PMID: 34298822

Full text available

Citations Cited by
11
Personalized [177Lu]Lutetium-PSMA Therapy for Patients with Pre-Treated Castration-Resistant Prostate Cancer: A Single Institution Experience from a Comprehensive Cancer Centre
Personalized [177Lu]Lutetium-PSMA Therapy for Patients with Pre-Treated Castration-Resistant Prostate Cancer: A Single Institution Experience from a Comprehensive Cancer Centre
Material Type:
Article 		Add to My Research

Personalized [177Lu]Lutetium-PSMA Therapy for Patients with Pre-Treated Castration-Resistant Prostate Cancer: A Single Institution Experience from a Comprehensive Cancer Centre

Cancers, 2023-06, Vol.15 (12), p.3216 [Peer Reviewed Journal]

COPYRIGHT 2023 MDPI AG ;2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2023 by the authors. 2023 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers15123216 ;PMID: 37370826

Full text available

Citations Cited by
12
Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
Material Type:
Article 		Add to My Research

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225

EJNMMI research, 2022-10, Vol.12 (1), p.65-11, Article 65 [Peer Reviewed Journal]

The Author(s) 2022 ;2022. The Author(s). ;The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 2191-219X ;EISSN: 2191-219X ;DOI: 10.1186/s13550-022-00935-6 ;PMID: 36182983

Full text available

Citations Cited by
13
Short-Interval, Low-Dose Peptide Receptor Radionuclide Therapy in Combination with PD-1 Checkpoint Immunotherapy Induces Remission in Immunocompromised Patients with Metastatic Merkel Cell Carcinoma
Short-Interval, Low-Dose Peptide Receptor Radionuclide Therapy in Combination with PD-1 Checkpoint Immunotherapy Induces Remission in Immunocompromised Patients with Metastatic Merkel Cell Carcinoma
Material Type:
Article 		Add to My Research

Short-Interval, Low-Dose Peptide Receptor Radionuclide Therapy in Combination with PD-1 Checkpoint Immunotherapy Induces Remission in Immunocompromised Patients with Metastatic Merkel Cell Carcinoma

Pharmaceutics, 2022-07, Vol.14 (7), p.1466 [Peer Reviewed Journal]

2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2022 by the authors. 2022 ;ISSN: 1999-4923 ;EISSN: 1999-4923 ;DOI: 10.3390/pharmaceutics14071466 ;PMID: 35890361

Full text available

Citations Cited by
14
Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT
Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT
Material Type:
Article 		Add to My Research

Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT

Pharmaceutics, 2022-06, Vol.14 (6), p.1278 [Peer Reviewed Journal]

2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2022 by the authors. 2022 ;ISSN: 1999-4923 ;EISSN: 1999-4923 ;DOI: 10.3390/pharmaceutics14061278 ;PMID: 35745849

Full text available

Citations Cited by
15
In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2nd Cycle Is Better Predictor of Overall Survival of Prostate Cancer Patients Treated With 177Lu-PSMA
In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2nd Cycle Is Better Predictor of Overall Survival of Prostate Cancer Patients Treated With 177Lu-PSMA
Material Type:
Article 		Add to My Research

In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2nd Cycle Is Better Predictor of Overall Survival of Prostate Cancer Patients Treated With 177Lu-PSMA

Frontiers in oncology, 2021-03, Vol.11, p.578093-578093 [Peer Reviewed Journal]

Copyright © 2021 Prasad, Huang, Prasad, Makowski, Czech and Brenner 2021 Prasad, Huang, Prasad, Makowski, Czech and Brenner ;ISSN: 2234-943X ;EISSN: 2234-943X ;DOI: 10.3389/fonc.2021.578093 ;PMID: 33816225

Full text available

Citations Cited by
16
A Multi-Institutional Analysis of Prostate Cancer Patients With or Without 68Ga-PSMA PET/CT Prior to Salvage Radiotherapy of the Prostatic Fossa
A Multi-Institutional Analysis of Prostate Cancer Patients With or Without 68Ga-PSMA PET/CT Prior to Salvage Radiotherapy of the Prostatic Fossa
Material Type:
Article 		Add to My Research

A Multi-Institutional Analysis of Prostate Cancer Patients With or Without 68Ga-PSMA PET/CT Prior to Salvage Radiotherapy of the Prostatic Fossa

Frontiers in oncology, 2021-10, Vol.11, p.723536-723536 [Peer Reviewed Journal]

Copyright © 2021 Schmidt-Hegemann, Zamboglou, Thamm, Eze, Kirste, Spohn, Li, Stief, Bolenz, Schultze-Seemann, Bartenstein, Prasad, Ganswindt, Grosu, Belka, Mayer and Wiegel. ;Copyright © 2021 Schmidt-Hegemann, Zamboglou, Thamm, Eze, Kirste, Spohn, Li, Stief, Bolenz, Schultze-Seemann, Bartenstein, Prasad, Ganswindt, Grosu, Belka, Mayer and Wiegel 2021 Schmidt-Hegemann, Zamboglou, Thamm, Eze, Kirste, Spohn, Li, Stief, Bolenz, Schultze-Seemann, Bartenstein, Prasad, Ganswindt, Grosu, Belka, Mayer and Wiegel ;ISSN: 2234-943X ;EISSN: 2234-943X ;DOI: 10.3389/fonc.2021.723536 ;PMID: 34660290

Full text available

Citations Cited by
17
Patlak Slope versus Standardized Uptake Value Image Quality in an Oncologic PET/CT Population: A Prospective Cross-Sectional Study
Patlak Slope versus Standardized Uptake Value Image Quality in an Oncologic PET/CT Population: A Prospective Cross-Sectional Study
Material Type:
Article 		Add to My Research

Patlak Slope versus Standardized Uptake Value Image Quality in an Oncologic PET/CT Population: A Prospective Cross-Sectional Study

Diagnostics (Basel), 2024-05, Vol.14 (9), p.883 [Peer Reviewed Journal]

COPYRIGHT 2024 MDPI AG ;2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 2075-4418 ;EISSN: 2075-4418 ;DOI: 10.3390/diagnostics14090883 ;PMID: 38732298

Full text available

Citations Cited by
18
Changes of Radiation Treatment Concept Based on 68Ga-PSMA-11-PET/CT in Early PSA-Recurrences After Radical Prostatectomy
Changes of Radiation Treatment Concept Based on 68Ga-PSMA-11-PET/CT in Early PSA-Recurrences After Radical Prostatectomy
Material Type:
Article 		Add to My Research

Changes of Radiation Treatment Concept Based on 68Ga-PSMA-11-PET/CT in Early PSA-Recurrences After Radical Prostatectomy

Frontiers in oncology, 2021-06, Vol.11, p.665304-665304 [Peer Reviewed Journal]

Copyright © 2021 Bottke, Miksch, Thamm, Krohn, Bartkowiak, Beer, Bolenz, Beer, Prasad and Wiegel 2021 Bottke, Miksch, Thamm, Krohn, Bartkowiak, Beer, Bolenz, Beer, Prasad and Wiegel ;ISSN: 2234-943X ;EISSN: 2234-943X ;DOI: 10.3389/fonc.2021.665304 ;PMID: 34141618

Full text available

Citations Cited by
19
A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management
A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management
Material Type:
Article 		Add to My Research

A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management

Endocrine Connections, 2016-09, Vol.5 (5), p.174-187 [Peer Reviewed Journal]

2016 The authors ;2016 The authors. ;2016 The authors 2016 ;ISSN: 2049-3614 ;EISSN: 2049-3614 ;DOI: 10.1530/EC-16-0043 ;PMID: 27582247

Full text available

Citations Cited by
20
Clinical trials involving positron emission tomography and prostate cancer: an analysis of the ClinicalTrials.gov database
Clinical trials involving positron emission tomography and prostate cancer: an analysis of the ClinicalTrials.gov database
Material Type:
Article 		Add to My Research

Clinical trials involving positron emission tomography and prostate cancer: an analysis of the ClinicalTrials.gov database

Radiation oncology (London, England), 2018-06, Vol.13 (1), p.113-113, Article 113 [Peer Reviewed Journal]

COPYRIGHT 2018 BioMed Central Ltd. ;Copyright © 2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and conditions, you may use this content in accordance with the terms of the License. ;The Author(s). 2018 ;ISSN: 1748-717X ;EISSN: 1748-717X ;DOI: 10.1186/s13014-018-1057-3 ;PMID: 29914515

Full text available

Citations Cited by

Results 1 - 20 of 54  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (47)
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait